目的 探討地塞米松聯(lián)合屈螺酮炔雌醇治療多囊卵巢綜合征的臨床療效。方法 選取2013年6-2015年7月連云港市東方醫(yī)院收治的多囊卵巢綜合征患者80例，隨機(jī)分為對(duì)照組和治療組，每組各40例。對(duì)照組患者在月經(jīng)周期第5天起口服屈螺酮炔雌醇片，1片/次，1次/d，連續(xù)服用21 d為1個(gè)周期，停藥后待患者出現(xiàn)撤退性出血的第5天進(jìn)行下個(gè)周期的治療。治療組在對(duì)照組治療基礎(chǔ)上在患者月經(jīng)周期第1天起口服醋酸地塞米松片，1片/次，1次/d，直到患者排卵后停止服用。兩組均連續(xù)治療3個(gè)周期。對(duì)比兩組患者治療前后激素水平、胰島素抵抗、空腹胰島素水平等。結(jié)果 治療后，兩組患者的促黃體生成素（LH）、睪酮（T）水平均顯著下降，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組LH、T水平低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患者的空腹胰島素（FIN）、計(jì)算胰島素抵抗指數(shù)（HOMA-IR）均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組FIN、HOMA-IR低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和治療組的排卵率分別為37.5%、65.0%，妊娠率分別為25.0%、52.5%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 地塞米松聯(lián)合屈螺酮炔雌醇治療多囊卵巢綜合征具有較好的臨床療效，能明顯改善患者胰島素抵抗和性激素水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of dexamethasone combined with drospirenone and ethinylestradiol in treatment of polycystic ovary syndrome. Methods Patients (80 cases) with polycystic ovary syndrome in Oriental Hospital and Foreign Related Hospital of Lianyungang from June 2013 to July 2015 were randomly divided into control and treatment groups, and each group had 40 cases. The patients in the control group were po administered with Drospirenone and Ethinylestradiol Tablets from day 5 of the menstrual cycle, 1 tablet/time, once daily, 21 d was as one cycle. The next cycle of treatment was proceeded on day 5 of withdrawal bleeding. The patients in the treatment group were po administered with Dexamethasone Acetate Tablets on the basis of the control group from day 1 of menstrual cycle, 1 tablet/time, once daily. They stopped taking until ovulation. The patients in two groups were treated for three cycles. The levels of hormone, insulin resistance, and fasting insulin in two groups before and after treatment were compared. Results After treatment, the levels of LH and T in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the levels of LH and T in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of FIN and HOMA-IR in treatment group were significantly decreased, and the difference was significant in the same group (P<0.05). After treatment, the levels of FIN and HOMA-IR in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05).The ovulation rates in the control and treatment groups were 37.5% and 65.0%, and the pregnancy rates in two groups were 25.0% and 52.5%, respectively, and there were differences between two groups (P<0.05). Conclusion Dexamethasone combined with drospirenone and ethinylestradiol has clinical curative effect in treatment of polycystic ovary syndrome, and can significantly improve insulin resistance and sex hormone levels, which has a certain clinical application value.